Skip to content


    DEA Class; Rx

    Common Brand Names; Tindamax

    • Antiparasitic Agents; 
    • Nitroimidazoles

    Oral nitroimidazole antimicrobial
    Used for trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis
    Limit use to approved indications and short-term only

    Indicated for

    • Amebiasis, Intestinal
    • Amebic Liver Abscess
    • Giardiasis or Trichomoniasis
    • Bacterial Vaginosis (Nonpregnant)


    1st trimester of pregnancy

    Patients with Cockayne syndrome

    • Anorexia (2-3%)
    • Constipation (<1%)
    • Dizziness (<1%)
    • Dysgeusia (4-6%)
    • Dyspepsia (1-2%)
    • Headache (<1%)
    • Nausea (3-5%)
    • Vomiting (1-2%)
    • Weakness/fatigue/malaise (1-2%)

    Carcinogenicity has been seen in mice and rats treated chronically with nitroimidazole drugs, which are structurally related to tinidazole; although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects; however, it is unclear if positive tumor findings in lifetime rodent studies indicate a risk to patients taking a short course or single dose of the drug; use should be limited to approved indications only; avoid chronic use

    Caution in patients with history of blood dyscrasias or history of hepatic impairment

    Convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity, reported; appearance of abnormal neurologic signs demands the prompt discontinuation of therapy

    Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria

    Risk of bacterial overgrowth with prolonged treatment

    No safety & efficacy data on pediatric patients <3 years of age

    Therapy may result in Candida vaginitis, a fungal infection, when used to treat bacterial vaginosis

    Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes reported after initiation of metronidazole, another nitroimidazole drug, in patients with Cockayne syndrome

    Available published data from a case-control study and case report with use in pregnant women are insufficient to identify risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

    Limited published literature, based on breast milk sampling, reports that drug is present in human milk; there are no reports of adverse effects on breastfed infant and no information on effects on milk production


    2 g/day PO.


    2 g/day PO.


    50 mg/kg/dose (Max: 2 g/dose) PO.


    4 to 12 years: 50 mg/kg/dose (Max: 2 g/dose) PO.
    1 to 3 years: Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.



    • 250mg
    • 500mg